Reference health
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
30269-8/badge.svg){kind=icon}
16/16 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 16 checked references that resolve
resolves10.1016/S1470-2045(14)70330-4
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
resolves10.1200/JCO.2014.57.9557
Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?
resolves10.1200/JCO.2012.42.8532
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
resolves10.3109/0284186X.2012.752580
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial
resolves10.1200/JCO.2008.21.0807
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
resolves10.1200/JCO.2012.45.0973
Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
resolves10.1200/JCO.2014.57.2826
Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials
resolves10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
resolves10.1159/000357714
Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer
resolves10.1200/JCO.2013.53.2473
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type
<i>KRAS</i>
Exon 2 Metastatic Colorectal Cancer
resolves10.1016/j.ejca.2015.06.116
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
resolves10.1016/j.ejca.2015.03.026
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
resolves10.1093/annonc/mdv112
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
resolves10.1111/cas.12148
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial
The 5 references without a DOI — listed, not checked
no DOI — not checkedDeepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC
no DOI — not checkedCALGB/SWOG 80405: phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum
no DOI — not checkedRole of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials
no DOI — not checked10.1016/S1470-2045(16)30269-8_bib16
no DOI — not checkedFirst-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT)RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s1470-2045(16)30269-8"><img src="https://citestamp.com/citestamped/10.1016/s1470-2045(16)30269-8/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[30269-8/badge.svg)](https://citestamp.com/citestamped/10.1016/s1470-2045(16)30269-8)